Zacks Investment Research upgraded shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a buy rating in a research note issued to investors on Tuesday morning. Zacks Investment Research currently has $2.00 price objective on the biotechnology company’s stock.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
Separately, HC Wainwright reissued a buy rating and set a $8.60 target price (up previously from $6.50) on shares of Capricor Therapeutics in a research report on Friday, January 26th.
Capricor Therapeutics (NASDAQ CAPR) traded down $0.04 during midday trading on Tuesday, reaching $2.00. 621,900 shares of the company’s stock were exchanged, compared to its average volume of 660,068. The stock has a market cap of $52.45, a P/E ratio of -3.03 and a beta of -3.90. Capricor Therapeutics has a 1-year low of $0.63 and a 1-year high of $4.25.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Brown Advisory Inc. purchased a new position in Capricor Therapeutics during the 4th quarter valued at about $1,796,000. Virtu KCG Holdings LLC increased its position in Capricor Therapeutics by 571.9% during the 2nd quarter. Virtu KCG Holdings LLC now owns 179,301 shares of the biotechnology company’s stock valued at $149,000 after purchasing an additional 152,614 shares during the period. Belpointe Asset Management LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $249,000. Jane Street Group LLC purchased a new position in Capricor Therapeutics during the 3rd quarter valued at about $190,000. Finally, Wells Fargo & Company MN purchased a new position in shares of Capricor Therapeutics in the 3rd quarter worth approximately $107,000. 4.05% of the stock is currently owned by institutional investors and hedge funds.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.